Navigation Links
Schering-Plough Announces European Submission of Fertility Medicine Corifollitropin Alfa
Date:12/31/2008

f fluid in the abdomen and/or chest, weight gain and the occurrence of blood clots in the circulation. Contact your doctor without delay if you are experiencing any of these symptoms, also if they develop some days after the last injection has been given.

Rarely, blood clots may also occur in the absence of unwanted overstimulation of the ovaries (see also "Take special care with PUREGON").

Other side effects observed include headache and nausea.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

Additional Important Product Information

Complete product information can be found at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Puregon/H-086-PI-en.pdf

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription, animal health and consumer healthcare products. Schering-Plough's vision is to Earn Trust, Every Day with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the plans for, the potential of and the potential market for corifollitropin alfa. Forward-loo
'/>"/>

SOURCE Schering-Plough
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... 24, 2015 A report out ... the single best option for avoiding cardiovascular disease is ... level was the single most powerful predictor of death ... as diabetes and family history of premature death -- ... heart and lung fitness. , The Importance of Cardiovascular ...
(Date:5/23/2015)... May 23, 2015 On May 13, ... of a youngster's yogic power learned through meditation and ... Swami in Bangalore, India. , Yogamaatha, a nine-year-old girl ... 50 high profile professionals attending the 2015 Business Advocacy ... fluently -- blindfolded. , In a demonstration that ...
(Date:5/23/2015)... Diego, CA (PRWEB) May 23, 2015 ... especially small businesses, are finding it increasingly difficult to ... businesses which fail to provide adequate insurance for employees ... for businesses been such an integral part of a ... more affordable healthcare for businesses, Online USA Doctors has ...
(Date:5/23/2015)... CO (PRWEB) May 23, 2015 On May ... in MuckFest. The event was a 5k mud obstacle run ... more than 2 million people worldwide, and the reason we ... community,” said Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred ... Multiple Sclerosis Society.” , The event was not only attended ...
(Date:5/23/2015)... May 23, 2015 A live auction will ... from hospitals, surgery centers and other medical facilities around the ... including endoscopy, lab, radiology, surgery, anesthesia, exam and much more. ... 27 and Thursday, May 28 starting at 9:00am CDT each ... 1400 N. 25th Avenue, Melrose Park, IL 60160. Anyone ...
Breaking Medicine News(10 mins):Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 2Health News:Recent Mayo Clinic Studies Help to Highlight the Value of Cardio Testing 3Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Over 5,200 Lots of Medical Equipment Will Be Sold by Live Auction 2
... doctor was acquitted on Wednesday of murdering three of his ... Martin, 71, a retired army officer from North Wales, was ... the lives of three seriously ill men, after a six-week ... look into the deaths of other patients under the care ...
... the first to visualize a need for laboratories in the Mexican ... Sustainability Laboratory (BNSL), which extends over an area of 4000 square ... security force and deal with terrorism // with the help ... for the lab come from USA, State of New Mexico and ...
... Barry D. Weiss, professor of family and community medicine and ... among patients. // ,They developed a tool which is ... minute questionnaire with six questions based on an ice cream ... by the patient their health literacy can be calculated. ...
... Gabriella gobbi and his team from Universite de ... increases the level of endocannabinoids by blocking the ... are chemicals present in brain which is responsible ... brain receptors are triggered during exercises and other ...
... Internal Medicine this week have found that the standard ... kidney failure is useless. //The study conducted by researchers ... found that a treatment called "plasma exchange" in patients ... means that the money which is currently spent in ...
... study conducted by the University of Alberta has revealed that ... mental health before its parents divorce. //The study does not ... More attention should be paid to the child while the ... the event has already occurred, according to Dr. Lisa Strohschein. ...
Cached Medicine News:Health News:British Doctor cleared of murder 2
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
(Date:5/21/2015)... 2015 Research and Markets ... the "North American Active Wound Care Market ... Wound, & Ulcer), by End-User (In-Patient, & Out-Paient) ... to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,The ... to grow at a CAGR of 3.1% from ...
(Date:5/21/2015)...  Cardica, Inc. (Nasdaq: CRDC ) today announced that ... the company,s vice president of operations, was granted an option ... a per share exercise price of $0.43, the closing trading ... pursuant to Cardica, Inc.,s Inducement Plan, which was approved by ... 5653(c)(4) of the Nasdaq Global Market for equity grants to ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2Cardica Announces New Employment Inducement Grant 2
... Total quarterly revenues of $608 million increase 53 percent versus prior year; ... for prior year; Adjusted diluted EPS of $1.05 ... increases 2011 revenue guidance to a range of $2.72 to $2.80 billion; and ... a range of $4.55 to $4.65 and Reported or GAAP diluted EPS to ...
... Intercept Pharmaceuticals, Inc. (Intercept) and Les Laboratoires Servier ... worldwide ex-U.S. and Japan agreement for the discovery and ... type 2 diabetes and other metabolic indications. The collaboration ... proprietary bile acid analog chemistry and expertise targeting TGR5 ...
Cached Medicine Technology:Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 2Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 3Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 4Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 5Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 6Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 7Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 8Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 9Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 10Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 11Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 12Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 13Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 14Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 15Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 16Endo Pharmaceuticals Reports Second Quarter Revenues and Updates Financial Guidance, Reflecting the Acquisition of American Medical Systems 17Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes 2Intercept Pharmaceuticals and Servier Announce Agreement for Intercept's TGR5 Research Program in Type 2 Diabetes 3
... Antigen (PSA) derives its name from its ... gland. The majority of PSA circulates ... Serum concentrations of PSA are elevated ... hypertrophy (BPH) and prostatitis [1-3]. In addition, ...
... profitability by reducing ... simple test,sequences that ... by ancillary office ... 5 minutes. New ...
Vision Testing for Infants and Non-Verbal Patients,Using Preferential Looking....
Pediatric: Tumbling "E" Acuity, Binocular Balance, Supression, Fixation Disparity, Stereopsis...
Medicine Products: